Reuters
17 Sept 2026, 20:38 UTC · 20h ago
Verdict
Headline takes no side. We score XENE −0.80 across one claim — strongly bearish.
−0.80strongly bearish
More negative than 88% of ticker scores this week
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
Xenon Pharmaceuticals has temporarily paused new patient enrollment in clinical trials for its major depression and bipolar disorder drug due to mental and nervous system side effects.
Newannounced on Thursday, published 2026-09-17
More negative than 98% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 88% of ticker scores this week
The company paused clinical study enrollment due to reports of mental and nervous system-related side effects.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
1d ago
−30.6%
Price agrees with the score
$39.78 vs $57.35 close before publication (Sep 17) · not market-adjusted
XENE chart →
